Advertisements


Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer

Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer.....»»

Category: topSource: seekingalphaJun 12th, 2019

Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease......»»

Category: worldSource: nytJul 11th, 2019

UNC breakthrough could accelerate gene editing therapeutics

A breakthrough technique coming out of Chapel Hill has the potential to accelerate gene editing therapies, bringing more drugs to patients – and markets – quicker......»»

Category: topSource: bizjournalsJul 10th, 2019

Why Amicus Therapeutics" Stock Perked Up in June

What happened Shares of rare disease specialist Amicus Therapeutics NASDAQ FOLD gained a healthy 10 7 in June according to data from S amp P Global Market Intelligence What sparked this upswing Amicus stock appears to have been the beneficiary of a rising.....»»

Category: futuresSource: nasdaqJul 5th, 2019

First Week of August 16th Options Trading For Denali Therapeutics (DNLI)

Stock Options Channel.....»»

Category: topSource: redinewsJul 1st, 2019

Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine o.....»»

Category: topSource: insidermonkeyJun 29th, 2019

Denali Therapeutics initiated with a Buy at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 26th, 2019

Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals

Aldeyra Therapeutics Inc. shares were down 29% in premarket trade Tuesday, after the company said a trial of a treatment for.....»»

Category: topSource: marketwatchJun 25th, 2019

Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins

Gilead Sciences Inc. is partnering with Nurix Therapeutics, a biotech working on drugs to destroy disease-causing.....»»

Category: topSource: marketwatchJun 19th, 2019

Is CymaBay Therapeutics’ Liver Disease Trial Sunk?

CymaBay Therapeutics shares were nearly halved early Tuesday after the company provided an update from its midstage study of seladelpar for the treatment of nonalcoholic steatohepatitis......»»

Category: blogSource: 247wallstJun 11th, 2019

CymaBay Therapeutics Plummets 40% Following Liver Disease Data

CymaBay Therapeu.....»»

Category: blogSource: benzingaJun 11th, 2019

$4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the F.....»»

Category: topSource: bizjournalsJun 10th, 2019

Why Cara Therapeutics Could Rise Another 50%

Cara Therapeutics recently announced data from its late-stage trial in patients with chronic kidney disease. While there was a very positive reaction among investors, one analyst believes that this........»»

Category: blogSource: 247wallstMay 30th, 2019

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus......»»

Category: blogSource: 247wallstMay 29th, 2019

Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up

Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up.....»»

Category: topSource: seekingalphaMay 20th, 2019

BioLineRx has multiple catalysts coming in 2019, says H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 14th, 2019

Biotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics

Biotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics.....»»

Category: topSource: seekingalphaMay 9th, 2019

Cyclerion Therapeutics: This Spinoff Has Multiple Readouts Coming Up, Concerns Remain

Cyclerion Therapeutics: This Spinoff Has Multiple Readouts Coming Up, Concerns Remain.....»»

Category: topSource: seekingalphaMay 9th, 2019

Denali Therapeutics reports Q1 EPS (41c), consensus (40c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 8th, 2019

Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming Catalysts

Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming Catalysts.....»»

Category: topSource: seekingalphaMay 7th, 2019

Potentially Good News for Those Who Suffer From Pompe Disease

There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has reported pre-clinical data from its Pompe disease gene therapy program and........»»

Category: blogSource: 247wallstApr 30th, 2019